Abstract 126: Relationship Between Visceral Infarction and Ischemic Stroke Subtype

Stroke ◽  
2018 ◽  
Vol 49 (Suppl_1) ◽  
Author(s):  
Caitlin B Finn ◽  
Peter Hung ◽  
Praneil Patel ◽  
Ajay Gupta ◽  
Hooman Kamel
Stroke ◽  
2019 ◽  
Vol 50 (7) ◽  
pp. 1805-1811 ◽  
Author(s):  
Susumu Kobayashi ◽  
Shingo Fukuma ◽  
Tatsuyoshi Ikenoue ◽  
Shunichi Fukuhara ◽  
Shotai Kobayashi ◽  
...  

Background and Purpose— In Japan, nearly half of ischemic stroke patients receive edaravone for acute treatment. The purpose of this study was to assess the effect of edaravone on neurological symptoms in patients with ischemic stroke stratified by stroke subtype. Methods— Study subjects were 61 048 patients aged 18 years or older who were hospitalized ≤14 days after onset of an acute ischemic stroke and were registered in the Japan Stroke Data Bank, a hospital-based multicenter stroke registration database, between June 2001 and July 2013. Patients were stratified according to ischemic stroke subtype (large-artery atherosclerosis, cardioembolism, small-vessel occlusion, and cryptogenic/undetermined) and then divided into 2 groups (edaravone-treated and no edaravone). Neurological symptoms were evaluated using the National Institutes of Health Stroke Scale (NIHSS). The primary outcome was changed in neurological symptoms during the hospital stay (ΔNIHSS=NIHSS score at discharge−NIHSS score at admission). Data were analyzed using multivariate linear regression with inverse probability of treatment weighting after adjusting for the following confounding factors: age, gender, and systolic and diastolic blood pressure at the start of treatment, NIHSS score at admission, time from stroke onset to hospital admission, infarct size, comorbidities, concomitant medication, clinical department, history of smoking, alcohol consumption, and history of stroke. Results— After adjusting for potential confounders, the improvement in NIHSS score from admission to discharge was greater in the edaravone-treated group than in the no edaravone group for all ischemic stroke subtypes (mean [95% CI] difference in ΔNIHSS: −0.46 [−0.75 to −0.16] for large-artery atherosclerosis, −0.64 [−1.09 to −0.2] for cardioembolism, and −0.25 [−0.4 to −0.09] for small-vessel occlusion). Conclusions— For any ischemic stroke subtype, edaravone use (compared with no use) was associated with a greater improvement in neurological symptoms, although the difference was small (<1 point NIHSS) and of limited clinical significance.


2019 ◽  
Vol 403 ◽  
pp. 31-37 ◽  
Author(s):  
Anna Therese Bjerkreim ◽  
Andrej Netland Khanevski ◽  
Lars Thomassen ◽  
Henriette Aurora Selvik ◽  
Ulrike Waje-Andreassen ◽  
...  

Stroke ◽  
2019 ◽  
Vol 50 (Suppl_1) ◽  
Author(s):  
Shyam Prabhakaran ◽  
Steven R Messe ◽  
Dawn Kleindorfer ◽  
Eric E Smith ◽  
Gregg C Fonarow ◽  
...  

2016 ◽  
Vol 135 (2) ◽  
pp. 176-182 ◽  
Author(s):  
M. L. Schmitz ◽  
C. Z. Simonsen ◽  
M. L. Svendsen ◽  
H. Larsson ◽  
M. H. Madsen ◽  
...  

2010 ◽  
Vol 32 (6) ◽  
pp. 636-641 ◽  
Author(s):  
Yuetao Ma ◽  
Xingquan Zhao ◽  
Wei Zhang ◽  
Liping Liu ◽  
Yilong Wang ◽  
...  

2014 ◽  
Vol 21 (7) ◽  
pp. 1220-1224 ◽  
Author(s):  
Dae Sup Byun ◽  
Sang Won Han ◽  
Joong Hyun Park ◽  
Jeong Yeon Kim ◽  
Jong Sam Baik ◽  
...  

2011 ◽  
Vol 2011 ◽  
pp. 1-5 ◽  
Author(s):  
Latha Ganti Stead ◽  
Rachel M. Gilmore ◽  
M. Fernanda Bellolio ◽  
Anunaya Jain ◽  
Alejandro A. Rabinstein ◽  
...  

Introduction. Etiology of acute ischemic stroke (AIS) is known to significantly influence management, prognosis, and risk of recurrence.Objective. To determine if ischemic stroke subtype based on TOAST criteria influences mortality.Methods. We conducted an observational study of a consecutive cohort of patients presenting with AIS to a single tertiary academic center.Results. The study population consisted of 500 patients who resided in the local county or the surrounding nine-county area. No patients were lost to followup. Two hundred and sixty one (52.2%) were male, and the mean age at presentation was 73.7 years (standard deviation, SD = 14.3). Subtypes were as follows: large artery atherosclerosis 97 (19.4%), cardioembolic 144 (28.8%), small vessel disease 75 (15%), other causes 19 (3.8%), and unknown 165 (33%). One hundred and sixty patients died: 69 within the first 30 days, 27 within 31–90 days, 29 within 91–365 days, and 35 after 1 year. Low 90-, 180-, and 360-day survival was seen in cardioembolic strokes (67.1%, 65.5%, and 58.2%, resp.), followed for cryptogenic strokes (78.0%, 75.3%, and 71.1%). Interestingly, when looking into the cryptogenic category, those with insufficient information to assign a stroke subtype had the lowest survival estimate (57.7% at 90 days, 56.1% at 180 days, and 51.2% at 1 year).Conclusion. Cardioembolic ischemic stroke subtype determined by TOAST criteria predicts long-term mortality, even after adjusting for age and stroke severity.


2008 ◽  
Vol 51 (4) ◽  
pp. 524
Author(s):  
M.F. Bellolio ◽  
S. Enduri ◽  
S. Suravaram ◽  
L. Vaidyanathan ◽  
R.M. Gilmore ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document